A narrative review: CXC chemokines influence immune surveillance in obesity and obesity-related diseases: Type 2 diabetes and nonalcoholic fatty liver disease.

World health organization. Key facts about obesity and overweight. Available online: https://www.who.int/news-room/factsheets/detail/obesity-and-overweight . Accessed 21 Dec 2022.

Lopez KN, Baker-Smith C, Karamlou T, Gallegos FN, Pasquali S, Patel A, et al. Addressing social determinants of health and mitigating health disparities across the lifespan in congenital heart disease: a scientific statement from the american heart association. J Am Heart Assoc. 2022;11:1–21.

doi: 10.1161/JAHA.122.025358

Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes,and related disorders. Immunity. 2022;55:31–55.

pubmed: 35021057 pmcid: 8773457 doi: 10.1016/j.immuni.2021.12.013

Bakhtiyari M, Kazemian E, Kabir K, Hadaegh F, Aghajanian S, Mardi P, et al. Contribution of obesity and cardiometabolic risk factors in developing cardiovascular disease: a population – based cohort study. Sci Rep. 2022;12:1–10.

doi: 10.1038/s41598-022-05536-w

Lazarus E, Edward H. Cancer and obesity: an obesity medicine association (OMA) clinical practice statement (CPS) 2022. Obes Pillars. 2022;3:100026.

doi: 10.1016/j.obpill.2022.100026

Khan A, Ross HM, Parra NS, Chen SL, Chauhan K, Wang M, et al. Risk prevention and health promotion for non-alcoholic fatty liver diseases (NAFLD). Livers. 2022;2:264–82.

doi: 10.3390/livers2040022

Zhang J, Shi Y. In search of the holy grail: toward a unified hypothesis on mitochondrial dysfunction in age-related diseases. Cells. 2022;11:1906.

pubmed: 35741033 pmcid: 9221202 doi: 10.3390/cells11121906

Khanna D, Khanna S, Khanna P, Kahar P, Patel BM. Obesity: a chronic low-grade inflammation and its markers. Cureus. 2022;14:1–11.

Celik O, Yildiz BO. Obesity and physical exercise. Minerva Endocrinol. 2021;46:131–44.

doi: 10.23736/S2724-6507.20.03361-1

Cinkajzlová A, Mráz M, Haluzík M. Adipose tissue immune cells in obesity, type 2 diabetes mellitus and cardiovascular diseases. J Endocrinol. 2021;252:R1-22.

pubmed: 34592714 doi: 10.1530/JOE-21-0159

Uribe-Querol E, Rosales C. Neutrophils actively contribute to obesity-associated inflammation and pathological complications. Cells. 2022;11:1883.

pubmed: 35741012 pmcid: 9221045 doi: 10.3390/cells11121883

Scheurlen KM, Snook DL, Alfieri T, Littlefield AB, George B, Seraphine C et al. Obesity hormones and itaconate mediating inflammation in human colon cancer cells – Another lead to early-onset colon cancer? Heliyon. 2023:e13132.

Lu X, Wang Z, Ye D, Feng Y, Liu M, Xu Y, et al. The role of CXC chemokines in cardiovascular diseases. Font Pharmacol. 2022;12:3830.

Noh J, Jun M, Yang H, Lee B. Cellular and molecular mechanisms and effects of berberine on obesity-induced inflammation. Biomedicine. 2022;10:1739.

Zhang T, Tseng C, Zhang Y, Sirin O, Corn PG, Li-ning-tapia EM, et al. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun. 2016;7:1167.

Surmi BK, Hasty AH. The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vascul Pharmacol. 2010;52:27–36.

pubmed: 20026286 doi: 10.1016/j.vph.2009.12.004

Chavey C, Lazennec G, Iankova I, Teyssier J, Lagarrigue S, Clape C, et al. CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metabol. 2009;9:339–49.

doi: 10.1016/j.cmet.2009.03.002

Kobashi C, Asamizu S, Ishiki M, Iwata M, Usui I, Yamazaki K, et al. Inhibitory effect of IL-8 on insulin action in human adipocytes via MAP kinase pathway. J Inflamm. 2009;6:1–6.

doi: 10.1186/1476-9255-6-25

Nara N, Nakayama Y, Okamoto S, Tamura H, Kiyono M, Muraoka, et al. Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance. J Biol Chem. 2007;282:30794–803.

pubmed: 17724031 doi: 10.1074/jbc.M700412200

Hara T, Nakayama Y. CXCL14 and insulin action. Vitam Horm. 2009;80:107–23.

pubmed: 19251036 doi: 10.1016/S0083-6729(08)00605-5

Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev/Immunology. 2014;14:181–94.

pubmed: 24566915

Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol. 2009;86:513–28.

pubmed: 19542050 pmcid: 2735282 doi: 10.1189/JLB.0309135

Tokunaga R, Zhang W, Naseem M, Puccini A, BergerSoni MD, Shivani, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy. Cancer Treat Rev. 2019;63:40–7.

doi: 10.1016/j.ctrv.2017.11.007

Neumann K, Erben U, Kruse N, Wechsung K, Schumann M. Chemokine transfer by liver sinusoidal endothelial cells contributes to the recruitment of CD4 + T cells into the murine liver. PLoS ONE. 2015;10:1–19.

doi: 10.1371/journal.pone.0123867

Mabrouk N, Tran T, Sam I, Pourmir I, Gruel N, Tartour E. CXCR6 expressing T cells: Functions and role in the control of tumors. Front Immunol. 2022;1–9.

Wang L, Lin J, Ma X, Xu D, Shi C, Wang W, et al. Exosomal DLX6-AS1 from hepatocellular carcinoma cells induces M2 macrophage polarization to promote migration and invasion in hepatocellular carcinoma through microRNA-15a-5p / CXCL17 axis. J Experimental Clin Cancer Res. 2021;40:1–16.

doi: 10.1186/s13046-021-01973-z

Ramne S, Drake I, Ericson U, Nilsson J, Orho-melander M, Engström G, et al. Identification of inflammatory and disease-associated sugar and sugar-sweetened beverages and their role in type 2 diabetes risk. Nutrients. 2020;12:1–15.

doi: 10.3390/nu12103129

Miller MC, Mayo KH. Chemokines from a structural perspective. Int J Mol Sci. 2017;18:2088.

pubmed: 28974038 pmcid: 5666770 doi: 10.3390/ijms18102088

Pluchino N, Mamillapalli R, Moridi I, Tal R, Taylor HS. G-protein-coupled receptor CXCR7 is overexpressed in human and murine endometriosis. Reprod Sci. 2018;25:1168–74.

pubmed: 29587613 pmcid: 6346303 doi: 10.1177/1933719118766256

Hattermann K, Mentlein R. An Infernal Trio: the chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology. Ann Anat. 2012;195:1–8.

Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer. 2006;42:0–10.

doi: 10.1016/j.ejca.2006.01.006

Mellado M, Rodr M, Mart C. Chemokine signaling and functional response: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol. 2001;19:397–421.

pubmed: 11244042 doi: 10.1146/annurev.immunol.19.1.397

Neves SR. G protein pathways. Science. 2002;296:1–5.

doi: 10.1126/science.1071550

Milligan G, Kostenis E. Heterotrimeric G-proteins: a short history. Br J Pharmacol. 2006;147:46-S55.

doi: 10.1038/sj.bjp.0706405

Tanegashima K, Suzuki K, Nakayama Y, Tsuji K, Shigenaga A, Otaka A, et al. CXCL14 is a natural inhibitor of the CXCL12 – CXCR4 signaling axis. FEBS Lett. 2013;587:1731–5.

pubmed: 23669361 doi: 10.1016/j.febslet.2013.04.046

Ouh Y, Cho HW, Lee JK, Choi SH. CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer. Tumor Biol. 2019;4:1–10.

Hwang S, He Y, Xiang X, Seo W, Kim S-J, Ren JM, Id T, Hwang O, He S, Xiang Y. Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology. 2020;72:412–29.

pubmed: 31705800 doi: 10.1002/hep.31031

Mueller AM, Kleemann R, Gart E, Duyvenvoorde W, Van, Verschuren L, Caspers M, et al. Cholesterol accumulation as a driver of hepatic inflammation under translational dietary conditions can be attenuated by a multicomponent medicine. Front Endocrinol. 2021;12:1–14.

doi: 10.3389/fendo.2021.601160

Ruebel ML, Cotter M, Sims CR, Moutos DM, Badger TM, Cleves MA, et al. Obesity modulates inflammation and lipid metabolism oocyte gene expression: a single-cell transcriptome perspective. J Clin Endocrinol Metab. 2017;102:2029–38.

pubmed: 28323970 pmcid: 5470765 doi: 10.1210/jc.2016-3524

Kobos L, Alqahtani S, Xia L, Coltellino V, Kishman R, McIlrath D, et al. Comparison of silver nanoparticle-induced inflammatory responses between healthy and metabolic syndrome mouse models. J Toxicol Environ Health. 2021;83:249–68.

doi: 10.1080/15287394.2020.1748779

Wen J, Wang L. Identification of key genes and their association with immune infiltration in adipose tissue of obese patients: a bioinformatic analysis. Adipocyte. 2022;11:401–12.

pubmed: 35894174 pmcid: 9336476 doi: 10.1080/21623945.2022.2104512

Fuente-Hernandez Marcela Angelica De la, Alanis-Manriquez EC, Ferat-Osorio E, Rodriguez-Gonzalez A, Lagunas LA-PKV-SJM-Z, Lagunas VM. Molecular changes in adipocyte-derived stem cells during their interplay with cervical cancer cells. Cell Oncol. 2022;45:85–101.

doi: 10.1007/s13402-021-00653-6

Herrero-Aguayo V, Sáez-Martínez P, López-Cánovas JL, Prados-Carmona JJ, Alcántara-Laguna MD, López FL, et al. Dysregulation of components of the inflammasome machinery after bariatric surgery: novel targets for a chronic disease. J Clin Endocrinol Metab. 2021;19:e4917–34.

Deiuliis JA, Oghumu S, Duggineni D, Zhong J, Rutsky J, Banerjee A, et al. CXCR3 modulates obesity-induced visceral adipose inflammation and systemic insulin resistance. Obesity. 2014;22:1264–74.

pubmed: 24124129 doi: 10.1002/oby.20642

Ma W, Gil HJ, Escobedo N, Benito-Martín A, Ximénez-Embún P, Muñoz J, et al. Platelet factor 4 is a biomarker for lymphatic-promoted disorders. JCI Insight. 2020;5:1–18.

doi: 10.1172/jci.insight.135109

Eldridge RC, Wentzensen N, Pfeiffer RM, Brinton LA, Patricia Hartge C, Guillemette TJ, Kemp, Ligia A, Pinto BT. Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease. Cancer Causes Control. 2021;31:309–20.

doi: 10.1007/s10552-020-01280-6

Ali MM, Naquiallah D, Qureshi M, Mirza MI, Hassan C, Masrur M, et al. DNA methylation profile of genes involved in inflammation and autoimmunity correlates with vascular function in morbidly obese adults. Epigenetics. 2022;17:93–109.

pubmed: 33487124 doi: 10.1080/15592294.2021.1876285

He W, Rebello O, Savino R, Terracciano R, Schuster-Klein C, Guardiola B, et al. TLR4 triggered complex inflammation in human pancreatic islets. Mol Basis Dis. 2019;1865:86–97.

doi: 10.1016/j.bbadis.2018.09.030

Auguet T, Bertran L, Binetti J, Aguilar C, Martínez S, Sabench F, et al. Relationship between IL-8 circulating levels and TLR2 hepatic expression in women with morbid obesity and nonalcoholic steatohepatitis. Int J Mol Sci. 2020;21:1–15.

doi: 10.3390/ijms21114189

Carpagnano GE, Spanevello A, Sabato R, Depalo A, Palladino GP, Bergantino L, et al. Systemic and airway inflammation in sleep apnea and obesity: the role of ICAM-1 and IL-8. Transl Res. 2010;155:35–43.

pubmed: 20004360 doi: 10.1016/j.trsl.2009.09.004

Ballak DB, Essen P, Van, Diepen JA, Van, Jansen H, Hijmans A. MAP3K8 (TPL2/COT) affects obesity-induced adipose tissue inflammation without systemic effects in humans and in mice. PLoS ONE. 2014;9:2–9.

doi: 10.1371/journal.pone.0089615

Thomas M, Cecilia B, Biniyam W, Marcus T, Marcus C. Association between obesity and periodontal risk indicators in adolescents. Int J Pediatr Obes. 2011;6:264–70.

doi: 10.3109/17477166.2010.495779

Yang X, Li M, Haghiac M, Catalano PM, Mouzon SH, Reserve CW. Causal relationship between obesity-related traits and TLR4- driven responses at the maternal–fetal interface. Diabetologia. 2017;59:2459–66.

doi: 10.1007/s00125-016-4073-6

Lima RS, Mattos RT, Medeiros NI, Kattah FM, Julya R, Nascimento S, et al. CXCL8 expression and methylation are correlated with anthropometric and metabolic parameters in childhood obesity. Cytokine. 2021;143:155538.

pubmed: 33926776 doi: 10.1016/j.cyto.2021.155538

Subudhi S, Drescher HK, Dichtel LE, Bartsch LM, Chung RT, Hutter MM, et al. Distinct hepatic gene-expression patterns of NAFLD in patients with obesity. Hepatol Commun. 2022;6:77–89.

pubmed: 34558849 doi: 10.1002/hep4.1789

Harakeh S, Kalamegam G, Pushparaj PN, Al-Hejin A, Alfadul SM, Al Amri T, et al. Chemokines and their association with body mass index among healthy Saudis. Saudi J Biol Sci. 2020;27:6–11.

pubmed: 31889810 doi: 10.1016/j.sjbs.2019.03.006

Duarte GV, Boeira V, Correia T, Porto-Silva L, Cardoso T, Macedo MN, et al. Osteopontin, CCL5 and CXCL9 are independently associated with psoriasis, regardless of the presence of obesity. Cytokine. 2015;74:287–92.

pubmed: 25972108 doi: 10.1016/j.cyto.2015.04.015

Hueso L, Ortega R, Selles F, Yun N, Ortega J, Civera M, et al. Upregulation of angiostatic chemokines IP-10 / CXCL10 and I-TAC / CXCL11 in human obesity and their implication for adipose tissue angiogenesis. Int J Obes. 2018;1–12.

Ruebel M, Shankar K, Gaddy D, Lindsey F, Badger T, Andres A et al. Maternal obesity is associated with ovarian inflammation and up-regulation of early growth response factor (Egr)-1. Am J Physiol Endocrinol Metab. 2016;1–27.

Lee H, Park J, Kang J, Kawada T, Yu R, Han I. Cytokine chemokine and chemokine receptor gene expression in the mesenteric adipose tissue of KKAy mice. Cytokine. 2009;46:160–5.

pubmed: 19250839 doi: 10.1016/j.cyto.2008.12.025

Ibet G, Vannan M, Eksteen D, Reyes B. NLRP3 receptor contributes to protection against experimental antigen-mediated cholangitis. Biosci Rep. 2020;40:1–9.

Wolfs MGM, Gruben N, Rensen SS, Verdam FJ, Greve JW, Driessen A, et al. Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity. Nutr Diabetes. 2015;5:1–7.

doi: 10.1038/nutd.2014.43

Arendt LM, Mccready J, Keller PJ, Baker DD, Naber SP, Seewaldt V, et al. Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis. Tumor Stem Cell Biol. 2013;73:6080–93.

Peng H, Zhang H, Zhu H. Blocking CXCR7-mediated adipose tissue macrophages chemotaxis attenuates insulin resistance and inflammation in obesity. Biochem Biophys Res Commun. 2016;479:649–55.

pubmed: 27693695 doi: 10.1016/j.bbrc.2016.09.158

Cereijo R, Cairo AG-NM, Eizirik DL, Marta Giralt FV. CXCL14, a brown adipokine that mediates brown-fat-to-macrophage communication in thermogenic adoptation. Cell Metabol. 2018;28:750–63.

doi: 10.1016/j.cmet.2018.07.015

Matsushita Y, Hasegawa Y, Takebe N, Onodera K, Shozushima M, Oda T, et al. Serum C-X-C motif chemokine ligand 14 levels are associated with serum C-peptide and fatty liver index in type 2 diabetes mellitus patients. J Diabetes Investig. 2021;12:1042–9.

pubmed: 33063457 doi: 10.1111/jdi.13438

Ryyti R, Pemmari A, Peltola R, Hämäläinen M, Moilanen. Effects of lingonberry (vaccinium vitis-idaea L.) supplementation on hepatic gene expression in high-fat diet fed mice. Nutrients. 2021;13:1–23.

doi: 10.3390/nu13113693

Jaume Padilla1 NTJSL, Zhang H, Cui J, Zuidema MY, Hill CZ. Vascular transcriptional alterations produced by juvenile obesity in Ossabaw swine. Physiol Genomics. 2013;16:1–42.

RyytiID R, Hamalainen M, Peltola R, Moilanen E. Beneficial effects of lingonberry (Vaccinium vitis-idaea L.) supplementation on metabolic and inflammatory adverse effects induced by high-fat diet in a mouse model of obesity. PLoS One. 2020;15:1–17.

Mcpherson KC, Shields CA, Poudel B, Johnson AC, Taylor L, Stubbs C, et al. Altered renal hemodynamics is associated with glomerular lipid accumulation in obese Dahl salt-sensitive leptin receptor mutant rats. Am J Physiol Renal Physiol. 2020;318:911–21.

doi: 10.1152/ajprenal.00438.2019

Denis GV, Sebastiani P, Andrieu G, Tran AH, Strissel KJ, Frank L, Lombardi. Relationships among obesity, type 2 diabetes and plasma cytokines in african american women. Obesity. 2018;25:1916–20.

doi: 10.1002/oby.21943

Schielke L, Zimmermann N, Hobelsberger S, Steininger J, Strunk A, Blau K, et al. Metabolic syndrome in psoriasis is associated with upregulation of CXCL16 on monocytes and a dysbalance in innate lymphoid cells. Front Immunol. 2022;13:1–10.

doi: 10.3389/fimmu.2022.916701

Hariharan N, Ashcraft KA, Svatek RS, Livi CB, Wilson D, Kaushik D, et al. Adipose tissue-secreted factors alter bladder cancer cell migration. J Obes. 2018;2018:1–10.

doi: 10.1155/2018/9247864

Chavey C, Fajas L. Drives obesity to diabetes, and further. Aging. 2009;1:674–7.

pubmed: 20157549 pmcid: 2806041 doi: 10.18632/aging.100064

Arias N, Aguirre L, Fernández-Quintela A, M González AL, Miranda J, Macarulla MT, et al. MicroRNAs involved in the browning process of adipocytes. J Physiol Biochem. 2015;72:509–21.

pubmed: 26695012 doi: 10.1007/s13105-015-0459-z

Juge-aubry CE, Somm E, Giusti V, Chicheportiche R, Verdumo C, Burger D, et al. Adipose tissue is a major source of interleukin-1 receptor antagonist upregulation in obesity and inflammation. Diabetes. 2003;52:1–7.

doi: 10.2337/diabetes.52.5.1104

Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. PNAS. 2003;100:7265–70.

pubmed: 12756299 pmcid: 165864 doi: 10.1073/pnas.1133870100

Bruun JM, Pedersen SB, Metabolism C, Amtssygehus A. Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab. 2000;86:1267–73.

Sindhu S, Kochumon S, Thomas R, Bennakhi A, Al-Mulla F, Ahmad R. Enhanced adipose expression of interferon regulatory factor (IRF)-5 associates with the Signatures of metabolic inflammation in diabetic obese patients. Cell. 2020;9:1–20.

Straczkowski M, Dzienis-straczkowska S, Ste A, Kowalska I, Szelachowska M, Kinalska IDA. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor alpha system. J Clin Endocrinol Metab. 2015;87:4602–6.

doi: 10.1210/jc.2002-020135

David JM, Dominguez C, Hamilton DH, Palena C. The IL-8/IL-8R axis: a double agent in tumor immune resistance. Vaccines. 2016;4:1–15.

doi: 10.3390/vaccines4030022

Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659–702.

pubmed: 24655300 doi: 10.1146/annurev-immunol-032713-120145

Gerhardt CC, Romero IA, Cancello R, Camoin L, Strosberg AD. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol. 2001;175:81–92.

pubmed: 11325518 doi: 10.1016/S0303-7207(01)00394-X

Saha A, Ahn S, Blando J, Su F, Kolonin MG. Proinflammatory CXCL12-CXCR4/CXCR7 signaling axis drives myc-induced prostate cancer in obese mice. Cancer Res. 2018;77:5158–68.

doi: 10.1158/0008-5472.CAN-17-0284

Su F, Daquinag AC, Ahn S, Saha A, Dai Y, Zhao Z, et al. Progression of prostate carcinoma is promoted by adipose stromal cell-secreted CXCL12 signaling in prostate epithelium. Precision Oncol. 2021;26:1–10.

Kim D, Kim J, Yoon JH, Ghim J, Yea K. CXCL12 secreted from adipose tissue recruits macrophages and induces insulin resistance in mice. Diabetologia. 2014;57:1456–65.

pubmed: 24744121 doi: 10.1007/s00125-014-3237-5

Schaerli P, Willimann K, Ebert LM, Walz A, Moser B, Bern C. Cutaneous CXCL14 targets blood precursors to epidermal niches for langerhans cell differentiation. Immunity. 2005;23:331–42.

pubmed: 16169505 doi: 10.1016/j.immuni.2005.08.012

Shurin GV, Ferris R, Tourkova IL, Lokshin A, Balkir L, Collins B, et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol. 2005;174:1–10.

doi: 10.4049/jimmunol.174.9.5490

Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD, et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res. 2004;64:8262–70.

pubmed: 15548693 doi: 10.1158/0008-5472.CAN-04-2056

Cao X, Zhang W, Wan T, He L, Chen T, Yuan Z, et al. Molecular cloning and characterization of a novel CXC chemokine macrophage inflammatory protein-2 γ chemoattractant for human neutrophils and dendritic cells. J Immunol. 2000;165:1–10.

doi: 10.4049/jimmunol.165.5.2588

Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, Wu H, et al. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol. 2000;156:1937–50.

pubmed: 10854217 pmcid: 1850081 doi: 10.1016/S0002-9440(10)65067-5

Sleeman MA, Fraser JK, Murison JG, Kelly SL, Prestidge RL, Palmer DJ, et al. B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR α-chemokine Matthew. Int Immunol. 2000;12:677–89.

pubmed: 10784614 doi: 10.1093/intimm/12.5.677

Hromas R, Broxmeyer HE, Kim C, Nakshatri H, Ii KC, Azam M, et al. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun. 1999;706:703–6.

doi: 10.1006/bbrc.1999.0257

Hara T, Tanegashima K. Pleiotropic functions of the CXC-type chemokine CXCL14 in mammals. J Biochem. 2012;151:469–76.

pubmed: 22437940 doi: 10.1093/jb/mvs030

Meuter S, Schaerli P, Roos RS, Brandau O, Bo MR, Andrian UH, Von, et al. Murine CXCL14 is dispensable for dendritic cell function and localization within peripheral tissues. Mol Cell Biol. 2007;27:983–92.

pubmed: 17130243 doi: 10.1128/MCB.01648-06

Tanegashima K, Okamoto S, Nakayama Y, Taya C, Shitara H, Ishii R. CXCL14 deficiency in mice attenuates obesity and inhibits feeding behavior in a novel environment. POLS ONE. 2010;5:1–9.

Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21:201–23.

pubmed: 34815532 doi: 10.1038/s41573-021-00337-8

Kastanias P, Mackenzie K, Robinson S, Wang W. Medical complications resulting from severe obesity. Psychiatr Care Severe Obes. 2017;49–73.

Butler AE, Janson J, Bonner-weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–10.

pubmed: 12502499 doi: 10.2337/diabetes.52.1.102

Ashcroft FM, Rorsman P. Diabetes mellitus and the β-cell: the last ten years. Cell. 2012;148:1160–71.

pubmed: 22424227 pmcid: 5890906 doi: 10.1016/j.cell.2012.02.010

Leea B-C. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta. 2015;1842:446–62.

doi: 10.1016/j.bbadis.2013.05.017

Popov SS, Kryl’skii ED, Shulgin KK, Raskina EA, Popova TN, Pashkov AN, et al. Inflammation is associated with impairment of oxidative status, carbohydrate and lipid metabolism in type 2 diabetes complicated by non-alcoholic fatty liver disease. Minerva Endocrinol. 2022;47:304–13.

doi: 10.23736/S2724-6507.20.03257-5

Kumar M, Roe K, Nerurkar PV, Orillo B, Thompson KS, Verma S. Reduced immune cell infiltration and increased pro-inflammatory mediators in the brain of type 2 diabetic mouse model infected with west nile virus. J Neuroinflamm. 2014;11:1–17.

doi: 10.1186/1742-2094-11-80

Badr G, Badr BM, Mahmoud MH, Mohany M, Rabah DM, Garraud O. Treatment of diabetic mice with undenatured whey protein accelerates the wound healing process by enhancing the expression of MIP-1 α, MIP-2, KC, CX3CL1 and TGF- β in wounded tissue. Immunology. 2012;13:1–9.

Sajadi SMA, Hossein Khoramdelazad, Gholamhossein Hassanshahi HR, Hosseini J, Mahmoodi M, Arababadi MK, Derakhshan R, et al. Plasma levels of CXCL1 (GRO-alpha) and CXCL10 (IP-10) are elevated in type 2 diabetic patients: evidence for the involvement of inflammation and angiogenesis/angiostasis in this disease state. Clin Lab. 2013;59:133–7.

pubmed: 23505918 doi: 10.7754/Clin.Lab.2012.120225

Hakimizadeh E, Shamsizadeh A, Nazari M, Arababadi MK, Rezaeian M, Jamali RV, Poor Z, Nahideh M, Khorramdelazad H, Darakhshan S. Increased circulating levels of CXC chemokines is correlated with duration and complications of the disease in type-1 diabetes: a study on iranian diabetic patients. Clin Lab. 2013;59:531–7.

pubmed: 23865351 doi: 10.7754/Clin.Lab.2012.120518

Takahashi K, Ohara M, Sasai T, Homma H, Nagasawa K, Takahashi T, et al. Serum CXCL1 concentrations are elevated in type 1 diabetes mellitus, possibly reflecting activity of anti-islet autoimmune activity. Diab/Metab Res Rev. 2011;27:830–3.

doi: 10.1002/dmrr.1257

Nunemaker CS, Chung HG, Verrilli GM, Corbin KL, Upadhye A, Sharma PR. Increased circulating levels of CXC chemokines is correlated with duration and complications of the disease in type-1 diabetes: a study on iranian diabetic patients. Clin Lab. 2013;222:267–76.

Zhang J, Zhou R, Deng L, Cao G, Zhang Y, Xu H, et al. Huangbai liniment and berberine promoted wound healing in high-fat diet / streptozotocin-induced diabetic rats. Biomed Pharmacother. 2022;150:112948.

pubmed: 35430394 doi: 10.1016/j.biopha.2022.112948

Song M, Chen L, Zhang L, Li C, Wake J. Cryptotanshinone enhances wound healing in type 2 diabetes with modulatory effects on inflammation, angiogenesis and extracellular matrix remodelling. Pharm Biol. 2020;58:845–53.

pubmed: 32870741 pmcid: 8641666 doi: 10.1080/13880209.2020.1803369

Anuradha R, Saravanan M, Chandrakumar D, Menon A, Thiruvengadam K, Nutman TB, et al. Helminth infection modulates systemic pro- inflammatory cytokines and chemokines implicated in type 2 diabetes mellitus pathogenesis. PLoS Negl Trop Dis. 2020;14:e0008101.

doi: 10.1371/journal.pntd.0008101

Shen Z, Chen Q, Ying H, Ma Z, Bi X, Li X, et al. Identification of differentially expressed genes in the endothelial precursor cells of patients with type 2 diabetes mellitus by bioinformatics analysis. Exp Ther Med. 2020;19:499–510.

pubmed: 31897097

Cnop M, Welsh N, Jonas J, Jo A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54:97–107.

doi: 10.2337/diabetes.54.suppl_2.S97

Pedersen SS, Prause M, Williams K, Barrès R. Butyrate inhibits IL-1β-induced inflammatory gene expression by suppression of NF- κB activity in pancreatic beta cells. J Biol Chem. 2022;298:1–31.

doi: 10.1016/j.jbc.2022.102312

Burke SJ, Lu D, Sparer TE, Masi T, Goff MR, Karlstad MD, et al. NF-kB and STAT1 control CXCL1 and CXCL2 gene transcription. Am J Physiol Endocrinol Metab. 2014;306:131–49.

doi: 10.1152/ajpendo.00347.2013

Ma P, Zhang P, Chen S, Shi W, Ye J, Chen S. Immune cell landscape of patients with diabetic macular edema by single-cell RNA analysis. Font Pharmacol. 2021;12:1–14.

Leguina-ruzzi A, Valderas JP. BLT2 expression improves skin integrity and protects from alterations caused by hyperglycemia in type 2 diabetes. Dermato-Endocrinol. 2017;9:1–12.

doi: 10.1080/19381980.2016.1267078

Lin Q, Zhou W, Wang Y, Huang J, Hui X, Zhou Z, et al. Abnormal peripheral neutrophil transcriptome in newly diagnosed type 2 diabetes patients. J Diabetes Res. 2020;2020:1–10.

Cani PD, Bibiloni R, Knauf C, Neyrinck AM, Delzenne NM. Changes in gut microbiota control metabolic diet – induced obesity and diabetes in mice. Diabetes. 2008;57:1–12.

doi: 10.2337/db07-1403

Sonnenburg JL, Bäckhed F. Diet–microbiota interactions as moderators of human metabolism. Nature. 2016;535:56–64.

pubmed: 27383980 pmcid: 5991619 doi: 10.1038/nature18846

Cimini FA, Barchetta I, Porzia A, Mainiero F, Costantino C, et al. Circulating IL–8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile. Acta Diabetol. 2017;54:961–7.

Cui S, Zhu Y, Du J, Khan MN, Wang B, Wei J, et al. CXCL8 antagonist improves diabetic nephropathy in male mice of diabetes and attenuates high glucose-induced mesangial injury. Endocrinology. 2017;158:1671–84.

pubmed: 28387853 doi: 10.1210/en.2016-1781

Tang W, Lv Q, Zou XCJ, Shi ZLY. CD8 + T cell-mediated cytotoxicity toward schwann cells promotes diabetic peripheral neuropathy. Cell Physiol Biochem. 2013;32:827–37.

pubmed: 24080983 doi: 10.1159/000354485

Kochumon S, Arefanian H, Sindhu S, Al-Mulla F, Ahmad JT. Adipose tissue steroid receptor RNA activator 1 (SRA1) expression is associated with obesity, insulin resistance, and inflammation. Cells. 2021;10:2602.

pubmed: 34685582 pmcid: 8534244 doi: 10.3390/cells10102602

Ascaso P, Palanca A, Martinez-Hervás S, Sanz MJ, Ascaso JF, Piqueras L, et al. Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes. Int J Clin Pract. 2021;75:e14302.

pubmed: 33930221 doi: 10.1111/ijcp.14302

Santopaolo M, Sullivan N, Thomas AC, Alvino VV, Nicholson LB, Gu Y, et al. Activation of bone marrow adaptive immunity in type 2 diabetes: rescue by co-stimulation modulator abatacept. Font Immunol. 2021;12:609406.

doi: 10.3389/fimmu.2021.609406

N Y, GR MM, GH A. Serum levels of interleukin 10 (IL-10) in patients with type 2 diabetes. Iran Red Crescent Med J. 2011;13:751–2.

Humpert PM, Djuric Z, Zeuge U, Oikonomou D, Seregin Y, Laine K, et al. Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-1 receptor – dependent signaling. Mol Med. 2008;14:301–8.

pubmed: 18309377 pmcid: 2255559 doi: 10.2119/2007-00052.Humpert

Karimabad MN, Hassanshahi G. Significance of CXCL12 in type 2 diabetes mellitus and its associated complications. Inflammation. 2014;38:710–7.

doi: 10.1007/s10753-014-9981-3

Lu C, Ma J, Su J, Wang X, Liu W, Ge X. Serum stromal cell-derived factor-1 levels are associated with diabetic kidney disease in type 2 diabetic patients. Endocr J. 2021;68:1101–7.

pubmed: 33896872 doi: 10.1507/endocrj.EJ21-0039

Nätynki A, Leisti P, Tuusa J, Varpuluoma O, Ukkola O, Junttila J, et al. Use of gliptins reduces levels of SDF-1 / CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients. Front Immunol. 2022;13:1–13.

doi: 10.3389/fimmu.2022.942131

Liu S, Liu X, Xiong H, Wang W, Liu Y, Yin L, et al. CXCL13/CXCR5 signaling contributes to diabetes-induced tactile allodynia via activating pERK, pSTAT3, pAKT pathways and pro-inflammatory cytokines production in the spinal cord of male mice. Brain Behav Immun. 2019;80:711–4.

pubmed: 31100371 doi: 10.1016/j.bbi.2019.05.020

Jiang H, Yicun W, Meng J, Chen S, Wang J, Qiu Y, et al. Effects of transplanting bone marrow stromal cells transfected with CXCL13 on fracture healing of diabetic rats. Cell Physiol Biochem. 2018;49:123–33.

pubmed: 30134225 doi: 10.1159/000492848

Wu C, Chen X, Shu J, Lee C. Whole-genome expression analyses of type 2 diabetes in human skin reveal altered immune function and burden of infection. Oncotarget. 2017;8:34601–9.

pubmed: 28427244 pmcid: 5470994 doi: 10.18632/oncotarget.16118

Lu J, Chatterjee M, Schmid H, Beck S, Gawaz M. CXCL14 as an emerging immune and inflammatory modulator. J Inflamm. 2016;13:1–8.

doi: 10.1186/s12950-015-0109-9

Adamski V, Mentlein R, Lucius R, Synowitz M, Held-feindt J, Hattermann K. The chemokine receptor CXCR6 evokes reverse signaling via the transmembrane chemokine CXCL16. Int J Mol Sci. 2017;18:1468.

pubmed: 28698473 pmcid: 5535959 doi: 10.3390/ijms18071468

Xia Y, Entman ML, Wang Y. Critical role of CXCL16 in hypertensive kidney injury and fibrosis. Hypertension. 2013;62:1129–37.

pubmed: 24060897 doi: 10.1161/HYPERTENSIONAHA.113.01837

Fang Y, Henderson FC, Yi Q, Lei Q, Li Y, Chen N. Chemokine CXCL16 expression suppresses migration and invasiveness and induces apoptosis in breast cancer cells. Mediat Inflamm. 2014;2014:1–9.

Liang H, Liao M, Zhao W, Zheng X, Xu F, Wang H, et al. CXCL16 / ROCK1 signaling pathway exacerbates acute kidney injury induced by ischemia-reperfusion. Biomed Pharmacother. 2018;98:347–56.

pubmed: 29275176 doi: 10.1016/j.biopha.2017.12.063

Abdel-bakky MS, Alqasoumi A, Altowayan WM, Amin E, Darwish MA. Resveratrol inhibited ADAM10 mediated CXCL16-cleavage and T-cells recruitment to pancreatic β -cells in type 1 diabetes mellitus in mice. Pharmaceutics. 2022;14:594.

pubmed: 35335970 pmcid: 8955623 doi: 10.3390/pharmaceutics14030594

Zhao L, Wu F, Jin L, Lu T, Yang L, Pan X, et al. Serum CXCL16 as a novel marker of renal injury in type 2 diabetes mellitus. PLoS One. 2014;9:e87786.

pubmed: 24489966 pmcid: 3906379 doi: 10.1371/journal.pone.0087786

Gutwein P, Abdel-bakky MS, Doberstein K, Schramme A, Beckmann J, Schaefer L, et al. CXCL16 and oxLDL are induced in the onset of diabetic nephropathy CXCL16 and oxLDL are induced in the onset of diabetic nephropathy. Mol Med. 2009;13:3809–25.

Kato T, Hagiyama M, Ito A. Renal ADAM10 and 17: their physiological and medical meanings. Front Cell Dev Biol. 2018;6:153.

pubmed: 30460232 pmcid: 6232257 doi: 10.3389/fcell.2018.00153

El-Asrar AMA, Nawaz MI, Ahmad A, Alexandra De Zutter M, Mairaj Siddiquei MB, Allegaert E, Gikandi PW, et al. Evaluation of proteoforms of the transmembrane chemokines CXCL16 and CX3CL1, their receptors, and their processing metalloproteinases ADAM10 and ADAM17 in proliferative diabetic retinopathy. Front Immunol. 2021;11:601639.

pubmed: 33552057 pmcid: 7854927 doi: 10.3389/fimmu.2020.601639

Tawfik MS, Abdel-messeih PL, Nosseir NM, Heba HM. Circulating CXCL16 in type 2 diabetes mellitus egyptian patients. J Radiation Res Appl Sci. 2020;14:9–15.

Zhou F, Wang J, Wang K, Zhu X, Pang R, Li X, et al. Serum CXCL16 as a novel biomarker of coronary artery disease in type 2 diabetes mellitus: a pilot study. Ann Clin Lab Sci. 2016;46:184–9.

pubmed: 27098626

Lekva T, Michelsen AE, Aukrust P, Cecilie M, Roland P, Henriksen T, et al. CXC chemokine ligand 16 is increased in gestational diabetes mellitus and preeclampsia and associated with lipoproteins in gestational diabetes mellitus at 5 years follow-up. Diabetes Vasc Dis Res. 2017;14:525–33.

doi: 10.1177/1479164117728011

Brandon J, Perumpail MAK, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263–76.

doi: 10.3748/wjg.v23.i47.8263

Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377:2063–72.

pubmed: 29166236 doi: 10.1056/NEJMra1503519

Younossi ZM. Nonalcoholic fatty liver disease. Zobair M Younossi. 1999;1:57–62.

Angulo P. Non-alcoholic fatty liver disease. Med Progress. 2002;346:1221–31.

Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664–9.

pubmed: 10051466 doi: 10.1002/hep.510290347

Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.

pubmed: 10348825 doi: 10.1016/S0016-5085(99)70506-8

Adams LA, Lymp JF, Sauver JST, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21.

pubmed: 16012941 doi: 10.1053/j.gastro.2005.04.014

Day CP, James OF, Steatohepatitis. A tale of two hits? Gastroenterology. 1998;114:842–5.

pubmed: 9547102 doi: 10.1016/S0016-5085(98)70599-2

CP D. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005;129:375–8.

doi: 10.1053/j.gastro.2005.05.041

Silva HE, Da, Arendt BM, Noureldin SA, Therapondos G, Chb MBM, Guindi M, et al. A cross-sectional study assessing dietary intake and physical activity in canadian patients with nonalcoholic fatty liver disease vs healthy controls. J Acad Nutr Dietetics. 2014;114:1181–94.

doi: 10.1016/j.jand.2014.01.009

Abdallah J, Assaf S, Das A, Hirani V. Effects of anti–inflammatory dietary patterns on non– alcoholic fatty liver disease: a systematic literature review. Eur J Nutr. 2023;1–16.

Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147:577–94.

pubmed: 25066692 doi: 10.1053/j.gastro.2014.06.043

Seki Y-SR. Ekihiro. Chemokines and chemokine receptors in the development of NAFLD. Obes Fat Liver Liver Cancer. 2018;1061:45–53.

Nagata N, Chen G, Xu L, Ando H. An update on the chemokine system in the development of NAFLD. Medicina. 2022;58:761.

pubmed: 35744024 pmcid: 9227560 doi: 10.3390/medicina58060761

Chang B, Xu M, Zhou Z, Cai Y, Li M, Wang W, et al. Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for CXCL1. Hepatology. 2015;62:1070–85.

pubmed: 26033752 doi: 10.1002/hep.27921

Yang L, Miura K, Zhang B, Matsushita H, Yang YM, Liang S, et al. TRIF differentially regulates hepatic steatosis and inflammation/fibrosis in mice. Cell Mol Gastroenterol Hepatol. 2017;3:469–83.

pubmed: 28462384 pmcid: 5403956 doi: 10.1016/j.jcmgh.2016.12.004

Gart E, Duyvenvoorde W, Van, Caspers MPM, Trigt N, Van, Snabel J, Menke A, et al. Intervention with isoleucine or valine corrects hyperinsulinemia and reduces intrahepatic diacylglycerols, liver steatosis, and inflammation in ldlr – / –. Leiden mice with manifest obesity-associated NASH. FASEB J. 2022;36:1–18.

doi: 10.1096/fj.202200111R

Dai W, Sun Y, Jiang Z, Du K, Xia N, Zhong G. Key genes associated with non-alcoholic fatty liver disease and acute myocardial infarction. Med Sci Monit. 2020;26:1–11.

doi: 10.12659/MSM.922492

Ogawa Y, Imajo K, Honda Y, Kessoku T, Tomeno W. Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin. Sci Rep. 2018;1–14.

Saiman Y, Friedman SL. The role of chemokines in acute liver injury. Front Physiol. 2012;3:1–12.

doi: 10.3389/fphys.2012.00213

Bisset LR, Schmid P. Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr Opin Pulm Med. 2005;11:35–42.

pubmed: 15591886 doi: 10.1097/01.mcp.0000144502.50149.e0

Hamirani YS, Katz R, Nasir K, Zeb I, Blaha MJ, Blumenthal RS, et al. Association between inflammatory markers and Liver Fat: the multi-ethnic study of atherosclerosis. J Clin Exp Cardiol. 2014;5:1–7.

doi: 10.4172/2155-9880.1000344

Xia J, Xu X, Huang P, He M, Wang X. The potential of CXCL5 as a target for liver cancer-what do we know so far? Expert Opin Ther Targets. 2015;19:141–6.

pubmed: 25495348 doi: 10.1517/14728222.2014.993317

Xu X, Huang P, Yang B, Wang X, Xia J. Roles of CXCL5 on migration and invasion of liver cancer cells. J Transl Med. 2014;12:1–11.

doi: 10.1186/1479-5876-12-193

Leti F, Legendre C, Still CD, Chu X, Petrick A, Gerhard GS, et al. Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells. Transl Res. 2018;190:25–39.

doi: 10.1016/j.trsl.2017.09.001

Balkrishna A, Gohel V, Kumari P, Manik M, Bhattacharya K, Dev R. Livogrit prevents methionine-cystine deficiency induced nonalcoholic steatohepatitis by modulation of steatosis and oxidative stress in human hepatocyte-derived spheroid and in primary rat hepatocytes. Bioengineered. 2022;13:10811–26.

pubmed: 35485140 pmcid: 9208489 doi: 10.1080/21655979.2022.2065789

Mirshahi F, Aqbi HF, Cresswell K, Saneshaw M, Coleman C, Jacobs T, et al. Longitudinal studies can identify distinct inflammatory cytokines associated with the inhibition or progression of liver cancer. Liver Int. 2019;40:468–72.

pubmed: 31821689 doi: 10.1111/liv.14323

Cai X, Li Z, Zhang Q, Qu Y, Xu M, Wan X, et al. CXCL6-EGFR-induced kupffer cells secrete TGF‐β1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C-MYC/ EZH2 pathway in liver fibrosis. J Cell Mol Med. 2018;22:5050–61.

pubmed: 30106235 pmcid: 6156397 doi: 10.1111/jcmm.13787

Ivan Bieche T, Asselah I, Laurendeau D, Vidaud C, Degote V, Paradise P, Bedossa D-C, Valla P, Marcellinc M, Vidauda. ALaboratoire. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology. 2005;332:130–44.

pubmed: 15661146 doi: 10.1016/j.virol.2004.11.009

Chen M, Xing J, Pan D, Peng X, Gao P. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF- κ B pathway. Biomed Pharmacother. 2020;128:110286.

pubmed: 32521450 doi: 10.1016/j.biopha.2020.110286

Tuncer L, Özbek H, Topal C, Uygan S. The serum levels of IL-1\beta, IL-6,IL-8 and TNF-\alpha in nonalcoholic fatty liver. Turk J Med Sci. 2003;33:1–7.

Pan X, Kaminga AC, Liu A, Wen SW, Chen J, Luo J. Chemokines in non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Font Immunol. 2020;11:1–11.

Casilli F, Bianchini A, Gloaguen I, Biordi L, Alesse E, Festuccia C, et al. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. Biochem Pharmacol. 2005;69:385–94.

pubmed: 15652230 doi: 10.1016/j.bcp.2004.10.007

Nojima H, Konishi T, Freeman CM, Schuster RM, Japtok L, Kleuser B, et al. Chemokine receptors, CXCR1 and CXCR2, differentially regulate exosome release in hepatocytes. PLoS ONE. 2016;11:1–15.

doi: 10.1371/journal.pone.0161443

Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury. PNAS. 2004;101:11791–6.

pubmed: 15282370 pmcid: 511013 doi: 10.1073/pnas.0402090101

Wong AM, Ding X, Wong AM, Yu J, Kahn M, Wong N, et al. Unique molecular characteristics of NAFLD-associated liver cancer accentuate beta-catenin/ TNFRSF19-mediated immune evasion. J Hepatol. 2022;77:410–23.

pubmed: 35351523 doi: 10.1016/j.jhep.2022.03.015

Ipsen DH, Agerskov RH, Klaebel JH, Lykkesfeldt J, Nyborg PT. The development of nonalcoholic steatohepatitis is subjected to breeder dependent variation in guinea pigs. Sci Rep. 2021;11:1–10.

doi: 10.1038/s41598-021-82643-0

Youssry S, Kamel MA. Effect of folate supplementation on immunological and autophagy markers in experimental nonalcoholic fatty liver disease. Eur Cytokine Netw. 2019;30:135–43.

pubmed: 32096475

Ikeda A, Aoki N, Kido M, Iwamoto S, Nishiura H, Maruoka R, et al. Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice. Hepatology. 2014;60:224–36.

pubmed: 24700550 doi: 10.1002/hep.27087

Song XI, Shen Y, Lao Y, Tao Z, Zeng J, Wang J, et al. CXCL9 regulates acetaminophen –induced liver injury via CXCR3. Exp Ther Med. 2019;18:4845–51.

pubmed: 31772648 pmcid: 6861945

Semba T, Nishimura M, Nishimura S, Ohara O, Ishige T, Ohno S, et al. The FLS (fatty liver shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis. Gastroenterology. 2013;13:1–8.

Tacke F, Zimmermann HW, Berres M, Trautwein C, Wasmuth HE. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. Liver Int. 2011;6:840–9.

doi: 10.1111/j.1478-3231.2011.02504.x

Ángeles M, Sousa J, Zaida A, Moreno G, Tenor DP, Medrano LM, et al. CXCL9–11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross–sectional study. Clin Trans Med. 2017;6:0–9.

Wang Y, Huang J, Tian Z, Zhou Y. The role of CXC cytokines as biomarkers and potential targets in hepatocellular carcinoma. Math Biosci Eng. 2019;17:1381–95.

pubmed: 32233584 doi: 10.3934/mbe.2020070

Li L, Xia Y, Ji X, Wang H, Zhang Z, Lu P, et al. MIG/CXCL9 exacerbates the progression of metabolic-associated fatty liver disease by disrupting Treg/Th17 balance. Exp Cell Res. 2021;407:112801.

pubmed: 34461107 doi: 10.1016/j.yexcr.2021.112801

Zhu M, Li M, Zhou W, Yang Y, Li F, Zhang L, et al. Qianggan extract improved nonalcoholic steatohepatitis by modulating lncRNA / circRNA immune ceRNA networks. BMC Complement Altern Med. 2019;19:1–13.

doi: 10.1186/s12906-019-2577-6

Wang W, Liu X, Wei P, Ye F, Chen Y, Shi L, et al. SPP1 and CXCL9 promote non-alcoholic steatohepatitis progression based on bioinformatics analysis and experimental studies. Front Med. 2022;9:1–9.

Zheng J, Wu H, Zhang Z, Yao S. Dynamic co–expression modular network analysis in nonalcoholic fatty liver disease. Hereditas. 2021;158:31.

pubmed: 34419146 pmcid: 8380347 doi: 10.1186/s41065-021-00196-8

Xu Z, Zhang X, Lau J, Yu J. C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication. Expert Rev Mol Med. 2016;18:e16.

pubmed: 27669973 doi: 10.1017/erm.2016.16

Ibrahim SH, Hirsova P, Tomita K, Bronk SF, Nathan W, Harrison SA, et al. Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes. Hepatology. 2017;63:731–44.

doi: 10.1002/hep.28252

He W, Huang C, Zhang X, Wang D, Chen Y, Zhao Y, et al. Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis. Endocrine. 2021;73:52–64.

pubmed: 33837926 doi: 10.1007/s12020-021-02716-y

Jiang H, Mao T, Liu Y, Tan X, Sun Z, Cheng Y, et al. Protective effects and mechanisms of yinchen linggui zhugan decoction in HFD-induced nonalcoholic fatty liver disease rats based on network pharmacology and experimental verification. Front Pharmacol. 2022;13:1–14.

Luo N, Yang C, Zhu Y, Chen Q, Zhang B. Diosmetin ameliorates nonalcoholic steatohepatitis through modulating lipogenesis and inflammatory response in a STAT1/CXCL10-dependent manner. J Agric Food Chem. 2021;69:655–67.

pubmed: 33404223 doi: 10.1021/acs.jafc.0c06652

Bigorgne AE, Delbos LB, Naveau S, Dagher I, Prévot S, Gasselin ID, et al. Obesity-induced lymphocyte hyperresponsiveness to chemokines: a new mechanism of fatty liver inflammation in obese mice. Gastroenterology. 2008;134:1459–69.

pubmed: 18471520 doi: 10.1053/j.gastro.2008.02.055

Boujedidi H, Robert O, Bignon A, Anne-Marie Cassard-Doulcier M-LR, Gary-Gouy H, Hemon P, et al. CXCR4 dysfunction in non-alcoholic steatohepatitis in mice and patients. Clin Sci. 2015;128:257–67.

doi: 10.1042/CS20130833

Yu Z, Han-bo CAO, Wen-jun LI, Li Z. The CXCL12 (SDF-1)/ CXCR4 chemokine axis: oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy. Chin J Nat Med. 2018;16:801–10.

Li Y, Li N, Liu J, An X. Gr-1high Ly6G + myeloid-derived suppressor cells and their role in a murine model of non-alcoholic steatohepatitis Yue. Am J Transl Res. 2020;12:2827–42.

pubmed: 32655813 pmcid: 7344062

Wang S, Gao S, Li Y, Qian X, Luan J, Lv X. Emerging importance of chemokine receptor CXCR4 and its ligand in liver disease. Front Cell Dev Biol. 2021;9:1–15.

Wang H, Shao Y, Zhang S, Xie A, Ye Y, Shi L, et al. CXCL16 deficiency attenuates acetaminophen- induced hepatotoxicity through decreasing hepatic oxidative stress and inflammation in mice. Acta Biochim Biophys Sin. 2017;49:1–9.

pubmed: 27864283 doi: 10.1093/abbs/gmw112

Mcmahan RH, Porsche CE, Edwards MG, Rosen HR. Free fatty acids differentially downregulate chemokines in liver sinusoidal endothelial cells:insights into non-alcoholic fatty liver disease. PLoS One. 2016;11:1–14.

Wehr A, Baeck C, Ulmer F, Gassler N, Hittatiya K, Luedde T, et al. Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. PLoS One. 2014;9:1–9.

doi: 10.1371/journal.pone.0112327

Geissmann F, Cameron TO, Sidobre S, Manlongat N, Kronenberg M, Briskin MJ, et al. Intravascular immune surveillance by CXCR6 + NKT cells patrolling liver sinusoids. PLoS Biol. 2005;3:e113.

pubmed: 15799695 pmcid: 1073691 doi: 10.1371/journal.pbio.0030113

Zhu H, Zhang Q, Chen G. CXCR6 deficiency ameliorates ischemia-reperfusion injury by reducing the recruitment and cytokine production of hepatic NKT cells in a mouse model of non-alcoholic fatty liver disease. Int Immunopharmacol. 2019;72:224–34.

pubmed: 31002999 doi: 10.1016/j.intimp.2019.04.021

Wehr A, Baeck C, Heymann F, Niemietz M, Hammerich L, Martin C, et al. Chemokine receptor CXCR6-dependent hepatic NK T cell accumulation promotes inflammation and liver fibrosis. J Immunol. 2013;190:5226–36.

pubmed: 23596313 doi: 10.4049/jimmunol.1202909

Jiang L, Yang M, Li X, Wang Y, Zhou G, Zhao J. CXC motif ligand 16 promotes nonalcoholic fatty liver disease progression via hepatocyte – stellate cell crosstalk. J Clin Endocrinol Metab. 2018;103:3974–85.

pubmed: 30053055 doi: 10.1210/jc.2018-00762

Ma KL, Wu Y, Zhang Y, Wang GH, Hu ZB, Ruan XZ. Activation of the CXCL16 / CXCR6 pathway promotes lipid deposition in fatty livers of apolipoprotein E knockout mice and HepG2 cells. Am J Transl Res. 2018;10:1802–16.

pubmed: 30018721 pmcid: 6038063

Bijnen M, Josefs T, Cuijpers I, Maalsen CJ, Gaar J, Van De, Vroomen M, et al. Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice. Gut. 2017;0:1–11.

José L, Maravillas-Montero AM, Burkhardt, Peter A, Hevezi, Christina D, Carnevale, Martine J. Smit and AZ. GPR35/CXCR8 is the receptor of the mucosal chemokine CXCL17. J Immunol. 2016;194:29–33.

Weinstein EJ, Head R, Griggs DW, Sun D, Evans RJ, Swearingen ML, et al. VCC-1, a novel chemokine, promotes tumor growth. Biochem Biophys Res Commun. 2006;350:74–81.

pubmed: 16989774 doi: 10.1016/j.bbrc.2006.08.194

Pisabarro MT, Leung B, Kwong M, Corpuz R, Frantz GD, Chiang N, et al. Cutting edge: novel human dendritic cell- and monocyte-attracting chemokine-like protein identified by fold recognition methods. J Immunol. 2006;176:2069–73.

pubmed: 16455961 doi: 10.4049/jimmunol.176.4.2069

Wang L, Li H, Zhen Z, Yu W, Zeng H, Li L, et al. CXCL17 promotes cell metastasis and inhibits autophagy via the LKB1-AMPK pathway in hepatocellular carcinoma. Gene. 2018;690:129–36.

pubmed: 30597237 doi: 10.1016/j.gene.2018.12.043

Long J, Bai Y, Yang X, Lin J, Yang X, Wang D, et al. Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma. Cancer Cell Int. 2019;19:1–12.

doi: 10.1186/s12935-019-0817-y

Wu D, Zheng Z, Zhang Y, Fan S, Zhang Z, Wang Y. Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells. J Exp Clin Cancer Res. 2019;38:1–17.

doi: 10.1186/s13046-019-1239-3

Zhang L, He X, Jin T, Li G, Jin Z. Long non-coding RNA DLX6-AS1 aggravates hepatocellular carcinoma carcinogenesis by modulating miR-203a / MMP-2 pathway. Biomed Pharmacother. 2017;96:884–91.

pubmed: 29145165 doi: 10.1016/j.biopha.2017.10.056

Long J, Jiang C, Liu B, Fang S, Kuang M. MicroRNA-15a-5p suppresses cancer proliferation and division in human hepatocellular carcinoma by targeting BDNF. Tumor Biol. 2015;37:5821–8.

doi: 10.1007/s13277-015-4427-6

Li Y, Lin Q, Chang SUE, Zhang R, Wang J. Vitamin D3 mediates miR –15a–5p inhibition of liver cancer cell proliferation via targeting E2F3. Oncol Lett. 2020;20:292–8.

pubmed: 32565955 pmcid: 7285896 doi: 10.3892/ol.2020.11572

Qu Z, Feng J, Pan H, Jiang Y, Duan Y, Fa Z. Exosomes derived from HCC cells with different invasion characteristics mediated EMT through TGF- β / smad signaling pathway. Onco Targets Ther. 2019;12:6897–905.

pubmed: 31692540 pmcid: 6711569 doi: 10.2147/OTT.S209413

Li L, Yan J, Xu J, Liu C, Zhen Z, Chen H, et al. CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma. PLoS One. 2014;9:e110064.

pubmed: 25303284 pmcid: 4193880 doi: 10.1371/journal.pone.0110064

A narrative review: CXC chemokines influence immune surveillance in obesity and obesity-related diseases: Type 2 diabetes and nonalcoholic fatty liver disease.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Amin Ullah (A)

Ahmad Ud Din (A)

Wen Ding (W)

Zheng Shi (Z)

Sadaf Pervaz (S)

Bairong Shen (B)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH